News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD)'s Quad Pill Raises Kidney Questions, FDA Says


5/9/2012 8:12:01 AM

Gilead Sciences Inc. (GILD)’s experimental HIV pill Quad may need additional monitoring because of kidney damage seen in studies, U.S. regulators said. The four-in-one combination pill from Gilead, the largest maker of AIDS drugs, had a “generally acceptable” safety profile and retained more patients than standard treatments, Food and Drug Administration staff said in a report today. The agency asked advisers whether patients taking the drug should undergo extra testing to monitor for kidney complications.

Read at Bloomberg
Read at Reuters
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES